GGrantIndex
Sort

78,016 grants matching breast cancer

Optimizing Endocrine Therapy Adherence through Motivational Interviewing and Text Interventions

$621,496
Stephanie Brooke Wheeler · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA

A Randomized Trial of Physical Activity for Cognitive Functioning in Breast Cancer Survivors

$621,430
Sheri J Hartman · University Of California, San Diego · R01 · FY2019 · CA

COPY NUMBER VARIANTS AND EARLY-ONSET BREAST CANCER

$621,400
Paul Joseph Goodfellow · Washington University · R01 · FY2011 · CA

Behavioral Influences on Ovarian Cancer Progression: Role of Chemoresistance

$621,318
Susan K Lutgendorf · University Of Iowa · R01 · FY2017 · CA

Epidemiologic factors and survival by molecular subtypes of ovarian cancer

$621,252
Mary Anne Rossing · Fred Hutchinson Cancer Research Center · R01 · FY2015 · CA

Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer

$621,239
Ming You · Medical College Of Wisconsin · R01 · FY2019 · CA

Novel Biomarkers for Aromatase Inhibitor Therapy

$621,180
Washington University · R01 · FY2003 · CA

DNA Repair Phenotype the Missing Link in Breast Cancer Risk Assessment

$621,179
Mary Beth Terry · Columbia University Health Sciences · U01 · FY2021 · ES

Abbreviated Non-Contrast-Enhanced MRI for Breast Cancer Screening

$621,162
Brian Andrew Hargreaves · Stanford University · R01 · FY2021 · CA

Imaging Modulation of Immune Phenotype

$621,116
Katherine W Ferrara · Stanford University · R01 · FY2024 · CA

Reproductive Hormones - Biological and Molecular Actions

$621,103
Bert W O'Malley · Baylor College Of Medicine · R01 · FY2018 · HD

Reproductive Hormones - Biological and Molecular Actions

$621,103
Bert W O'Malley · Baylor College Of Medicine · R01 · FY2014 · HD

Reproductive Hormones - Biological and Molecular Actions

$621,103
Bert W O'Malley · Baylor College Of Medicine · R01 · FY2017 · HD

Automated Density Measures for Estimating Breast Cancer Risk and Therapy Response

$621,043
Celine M Vachon · Mayo Clinic Rochester · R01 · FY2013 · CA

Development of TGF-beta antagonists for cancer therapy

$621,015
Lalage Wakefield · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

High-resolution lower dose dedicated breast CT

$620,998
Srinivasan Vedantham · Univ Of Massachusetts Med Sch Worcester · R01 · FY2016 · CA

Biochemistry of Pre-mRNA Splicing

$620,984
Adrian R Krainer · Cold Spring Harbor Laboratory · R01 · FY2007 · GM

Resorbable Inferior Vena Cava Filter

$620,973
Mitchell Eggers · Adient Medical, Inc. · R44 · FY2016 · HL

Synergized Immune and Tumor Cell Bone Marrow Biomarkers to Predict Recurrence in Triple Negative Breast Cancer

$620,943
Rebecca L Aft · Washington University · R01 · FY2024 · CA

Environmental chemicals impair epigenetic suppression of the endogenous retrovirus HML-2 in human primordial germ cells, predisposing the next generation to malignancies through HML-2 reactivation

$620,940
Toshihiro Shioda · Massachusetts General Hospital · R01 · FY2024 · ES

Toward translation of a plant virus-based in situ vaccination nanotechnology

$620,922
Nicole Franziska Steinmetz · University Of California, San Diego · R01 · FY2025 · CA

Radiomic phenotypes of breast parenchyma and association with breast cancer risk and detection

$620,863
Celine M Vachon · Mayo Clinic Rochester · R01 · FY2019 · CA

Tyrosine phosphorylation of p27Kip1 as a biomarker to identify Cdk4/6 inhibitor response

$620,808
Janice L Brissette · Suny Downstate Medical Center · R01 · FY2022 · CA

NCI Community Oncology Research Program (NCORP) Community Sites

$620,783
Albert Denittis · Lankenau Institute For Medical Research · UG1 · FY2016 · CA

Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments

$620,740
Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2023 · CA